tbuckley/cabot-search huggingface dataset:
TCT-312 Spontaneous Myocardial Infarction After Revascularization in Left Main Disease: Analysis From the EXCEL Trial
Authors: Mahesh Madhavan, Akiko Maehara, Megha Prasad, Prakriti Gaba, Joseph Sabik, David Taggart, David Kandzari, Marie-Claude Morice, Akiko Fujino, Shmuel Chen, Bjorn Redfors, William Brown, Jeffrey W. Moses, Ori Ben-Yehuda, A. Pieter Kappetein, Patrick Serruys, Gregg Stone
Journal: Journal of the American College of Cardiology (2019)
Very Early Effects of Ibrutinib on Tumor and Immune Cells in Blood and Lymph Nodes in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Patients
Authors: Marzia Palma, Aleksandra Krstic, Anna Berglöf, Qing Wang, Emelie Blomberg, Stephan Meinke, Masood Kamali-Moghaddam, Qiujin Shen, Georg Jaremko, Jeanette Lundin, Eva Kimby, Petter Höglund, Robert Månsson, Anders Österborg, Edvard Smith
Journal: Blood (2016)
Distinct Nanoscale Calcium Channel and Synaptic Vesicle Topographies Contribute to the Diversity of Synaptic Function
Authors: Nelson Rebola, Maria Reva, Tekla Kirizs, Miklos Szoboszlay, Andrea Lőrincz, Gael Moneron, Zoltan Nusser, David A. DiGregorio
Journal: Neuron (2019)
TCT-116 Peri-Device Leaks Following Transcatheter Left Atrial Appendage Occlusion With the Amplatzer Devices: Correlation Between Cardiac CT and Transesophageal Echocardiography
Authors: Kasper Korsholm, Jesper Møller Jensen, Bjarne Nørgaard, Athanasios Samaras, Jens Erik Nielsen-Kudsk
Journal: Journal of the American College of Cardiology (2019)
TCT-839 The Relationship Between Winter Time and Increased Air Pollution Expressed as PM10 Concentration and the Frequency of Percutaneous Coronary Interventions in Patients With Acute Coronary Syndromes
Authors: Rafał Januszek, Bartłomiej Staszczak, Zbigniew Siudak, Krzysztof Plens, Stanislaw Bartus, Dariusz Dudek
Journal: Journal of the American College of Cardiology (2019)
Absorb Bioresorbable Scaffolds—Out of the Woods After 3 Years?
Authors: David P. Faxon
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
TCT-543 Long-Term Incidence and Details of Bleeding Event After Everolimus-Eluting Stent Implantation: 7- to 8-Year Follow-Up Outcomes
Authors: Katsuya Miura, Takenobu Shimada, Masanobu Ohya, Ryosuke Murai, Hidewo Amano, Shunsuke Kubo, Takeshi Tada, Hiroyuki Tanaka, Yasushi Fuku, Kazushige Kadota
Journal: Journal of the American College of Cardiology (2019)
TCT-194 A Fully Automated Classification and Segmentation of X-Ray Coronary Angiography Using Deep Learning Approach
Authors: Su Yang, Jihoon Kweon, Young-Hak Kim, Jae-Hyung Roh, Do-Yoon Kang, Pil Hyung Lee, Jung-Min Ahn, Duk-Woo Park, Seung-Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2019)
Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non–Small Cell Lung Cancer
Authors: Youngtae Jeong, Jessica A. Hellyer, Henning Stehr, Ngoc T. Hoang, Xiaomin Niu, Millie Das, Sukhmani K. Padda, Kavitha Ramchandran, Joel W. Neal, Heather Wakelee, Maximilian Diehn
Journal: Clinical Cancer Research (2019)

Abstract Purpose: Activation of NFE2L2 has been linked to chemoresistance in cell line models. Recently, somatic mutations that activate NFE2L2, including mutations in NFE2L2, KEAP1, or CUL3, have been found to be associated with poor outcomes in patients with non–small cell lung cancer (NSCLC). However, the impact of these mutations on chemoresistance remains incompletely explored. Experimental Design: We investigated the effect of Keap1 deletion on chemoresistance in cell lines from Trp53-based mouse models of lung squamous cell carcinoma (LSCC) and lung adenocarcinoma (LUAD). Separately, we identified 51 patients with stage IV NSCLC with KEAP1, NFE2L2, or CUL3 mutations and a matched cohort of 52 wild-type patients. Time to treatment failure after first-line platinum doublet chemotherapy and overall survival was compared between the two groups. Results: Deletion of Keap1 in Trp53-null murine LUAD and LSCC resulted in increased clonogenic survival upon treatment with diverse cytotoxic chemotherapies. In patients with NSCLC, median time to treatment failure (TTF) after first-line chemotherapy for the KEAP1/NFE2L2/CUL3-mutant cohort was 2.8 months compared with 8.3 months in the control group (P &amp;lt; 0.0001). Median overall survival (OS) was 11.2 months in the KEAP1/NFE2L2/CUL3-mutant group and 36.8 months in the control group (P = 0.006). Conclusions: Keap1 deletion confers chemoresistance in murine lung cancer cells. Patients with metastatic NSCLC with mutations in KEAP1, NFE2L2, or CUL3 have shorter TTF and OS after first-line platinum doublet chemotherapy compared with matched controls. Novel approaches for improving outcomes in this subset of patients with NSCLC are therefore needed.
CXCR6 regulates localization of tissue-resident memory CD8 T cells to the airways
Authors: Alexander N. Wein, Sean R. McMaster, Shiki Takamura, Paul R. Dunbar, Emily K. Cartwright, Sarah L. Hayward, Daniel T. McManus, Takeshi Shimaoka, Satoshi Ueha, Tatsuya Tsukui, Tomoko Masumoto, Makoto Kurachi, Kouji Matsushima, Jacob E. Kohlmeier
Journal: The Journal of Experimental Medicine (2019)

Resident memory T cells (TRM cells) are an important first-line defense against respiratory pathogens, but the unique contributions of lung TRM cell populations to protective immunity and the factors that govern their localization to different compartments of the lung are not well understood. Here, we show that airway and interstitial TRM cells have distinct effector functions and that CXCR6 controls the partitioning of TRM cells within the lung by recruiting CD8 TRM cells to the airways. The absence of CXCR6 significantly decreases airway CD8 TRM cells due to altered trafficking of CXCR6−/− cells within the lung, and not decreased survival in the airways. CXCL16, the ligand for CXCR6, is localized primarily at the respiratory epithelium, and mice lacking CXCL16 also had decreased CD8 TRM cells in the airways. Finally, blocking CXCL16 inhibited the steady-state maintenance of airway TRM cells. Thus, the CXCR6/CXCL16 signaling axis controls the localization of TRM cells to different compartments of the lung and maintains airway TRM cells.
TCT-734 Transcatheter Compared to Surgical Aortic Valve Replacement in Patients With Low Surgical Risk: A Meta-Analysis of All Randomized Controlled Trials
Authors: Aaqib Malik, Syed Zaid, Hasan Ahmad, Joshua Goldberg, Tanya Dutta, Cenap Undemir, Martin Cohen, Wilbert Aronow, Steven Lansman, Gilbert Tang
Journal: Journal of the American College of Cardiology (2019)
The CXCL12/CXCR4 and VEGF165/Nrp1 Pathways Have Differential Effects on Pathological Neo-Angiogenesis and Vascular Remodeling in Hemophilic Arthropathy
Authors: Tine L. Wyseure, Esther J. Cooke, Annette von Drygalski, Laurent O. Mosnier
Journal: Blood (2017)
Cutaneous disease in solid organ transplant recipients: A 5-year experience from a multidisciplinary medical-surgical transplant dermatology center
Authors: Rina Allawh, Melissa Hoffman, Kumar S. Nadhan, Mark Abdelmalek, Carrie Ann Cusack, Alden M. Doyle, Christina Lee Chung
Journal: Journal of the American Academy of Dermatology (2019)
What Is Safe Household Firearm Storage to Prevent Deaths Among US Youths?—Reply
Authors: Michael C. Monuteaux, Deborah Azrael, Matthew Miller
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Cytogenetic Abnormalities in Systemic Mastocytosis: Who Subcategory-Specific Incidence and Prognostic Impact Among 348 Informative Cases
Authors: Sahrish Shah, Animesh Pardanani, Yoseph Elala, Terra L. Lasho, Mrinal M. Patnaik, Kaaren K. Reichard, Curtis A. Hanson, Rhett P. Ketterling, Ayalew Tefferi
Journal: Blood (2018)
Venetoclax As a Single Agent and in Combination with PI3K-mTOR1/2 Kinase Inhibitors Against Ibrutinib Sensitive and Resistant Mantle Cell Lymphoma
Authors: Huijuan Jiang, Tint Lwin, Bijal D. Shah, Grace T Li, Yuan Ren, Michael W Yan, Lynn C. Moscinski, Xiaohong Zhao, Jianguo Tao
Journal: Blood (2017)
TCT-106 FFR in Nonculprits in STEMI: A Substudy of the COMPARE-ACUTE Trial
Authors: Zsolt Piroth, Elmir Omerovic, Bianca Boxma-de Klerk, Mohamed Abdel-Wahab, Franz-Josef Neumann, Gert Richardt, Pieter Smits
Journal: Journal of the American College of Cardiology (2019)
TCT-133 A Novel Concept of Catheter-Based Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy (Cerclage RF Ablation): Preliminary Animal Experiments in Swine Model
Authors: Min-Ku Chon, Eun-Seok Shin, Sang-Hyun Lee, Yong Hyun Park, June Hong Kim
Journal: Journal of the American College of Cardiology (2019)
TCT-187 Reduction of Strut Thickness Improves Early (up to 180 Days) Arterial Response to the Ultra-High Molecular Weight Amorphous PLLA Sirolimus-Eluting Bioresorbable Scaffolds in Normal Porcine Coronary Arteries
Authors: Pawel Gasior, Yanping Cheng, Jenn McGregor, Gerard Conditt, Juan Granada, Grzegorz Kaluza
Journal: Journal of the American College of Cardiology (2019)
TCT-667 Role of the Type of Carotid Stent and Cerebral Protection on Cerebral Microembolizaton During Carotid Artery Stenting. A Randomized Study Comparing Wallstent vs. Roadsaver Stent and Distal vs. Proximal Cerebral Protection
Authors: Piero Montorsi, Stefano Galli, Paolo Mario Ravagnani, Sarah Troiano, Giovanni Teruzzi, Daniela Trabattoni, Franco Fabbiocchi, Giuseppe Calligaris, Luca Grancini, Antonio Bartorelli, Stefano De Martini
Journal: Journal of the American College of Cardiology (2019)
Local failure after liver resection for hepatocellular carcinoma.
Authors: Elisha T. Fredman, Aryavarta M. S. Kumar, Galal El-Gazzaz, Federico Aucejo, Christopher Coppa, May Abdel-Wahab
Journal: Journal of Clinical Oncology (2013)

e15015 Background: Partial resection is the most common surgical management of primary hepatocellular carcinoma (HCC), yet long-term prognosis remains poor, with 3-year intrahepatic recurrence rates up to 80%. A percentage of these occur within close proximity to the original tumor site. We conducted a retrospective review of liver resections at the Cleveland Clinic to determine rates and patterns of close tumor failure to inform future treatment. Methods: 147 patients, identified from an IRB approved database, underwent partial hepatectomy for definitive treatment of HCC from 1996-2012. All were followed with CT or MRI for indications of recurrence, defined as characteristic or biopsy proven liver lesions absent from previous imaging. Patients were divided into two groups: local recurrence (≤2 cm from surgical margin, A) and non-local intrahepatic recurrence (&gt;2 cm from surgical margin, B). Logistic regression modeling was used for statistical analysis. Results: 73 (49.7%) patients had tumor recurrence, within a median time of 11.9 months (range: 1.6-69.9 months). 5 (6.8%) had extrahepatic recurrences only and were excluded from analysis. Groups A (n=19) and B (n=49) were demographically comparable. Mean tumor size was 8.9 cm (range: 2.6-14.5 cm) and 7.5 cm (range: 1.5-20 cm) respectively. In Group A, 6 (32%) had local lesions exclusively and 13 (68%) had concurrent local and non-local intrahepatic failure. Vascular invasion correlated with overall recurrence (p = 0.01). Patients with local recurrence were more likely to have a single lesion at initial diagnosis (p = 0.02) and had a shorter median time to surgery (p = 0.02). Presence of cirrhosis, tumor size, grade, margin status and tumor rupture were not significant correlates. Conclusions: In our population, 49.7% of patients had HCC recurrence. 26% of these recurrences were local failures. Vascular invasion correlated with overall recurrence. A single lesion and shorter time from diagnosis to surgery were associated specifically with local recurrence. Our findings open the possibility of employing intra-operative and/or adjuvant radiation therapy, which have demonstrated good local control with limited toxicity in other cancers, for patients at increased risk of local failure of HCC.
International, Practice-Based Recommendations for Prediction of Bleedings and Anti-Platelet/Anti-Coagulant (AP/AC) Co-Medications in CLL Patients Taking Ibrutinib
Authors: Evgeny Nikitin, Jennifer Series, Aleksandr Poletaev, Mikhail Panteleev, Georg Hopfinger, Vadim Ptushkin, Ulrich Jaeger, Bernard Payrastre, Loic Ysebaert
Journal: Blood (2017)
TCT-601 Concomitant Renal Sympathetic Denervation With Pulmonary Vein Isolation vs. Pulmonary Vein Isolation Alone Among Patients With Drug-Resistant Atrial Fibrillation and Hypertension: A Meta-Analysis
Authors: Mark Terence Mujer, Mohit Turagam, Varunsiri Atti, Jalaj Garg, Poonam Velagapudi, Kuladeep Gidda, Smit Patel, Supratik Rayamajhi, Dhanunjaya Lakkireddy
Journal: Journal of the American College of Cardiology (2019)
Expression of PTEN, pAkt, pS6, and Cyclin D1 on ER-positive breast cancer tissues using biomarker assays
Authors: Sienna Yoast, Anne Oster, Kirsten Mortensen, Birgitte Jepsen, Therese Phillips, Karin Salomon, Zunde Wang, Marianne Thisted, Miu Chau, Ole Rasmussen
Journal: Cancer Research (2007)

291  Alterations in various signaling pathways can result in escape from normal cell cycle control, potentially leading to deregulated cell proliferation and thus cancer development. Among these is the PI3K-mTOR signaling pathway (including PTEN, Akt, and S6), which is deregulated in several cancer types. Currently, several kinase inhibitors targeting this pathway are being developed and tested in clinical trials. Evaluation of the expression profile of signaling molecules of the PI3K-mTOR pathway might guide the development of these targeted therapies. The availability of high quality biomarker assays utilizing highly specific primary antibodies is crucial for expression profile studies of the PI3K-mTOR signaling pathway. Here we report the use of 4 biomarker prototype assays (PTEN, pS473 Akt, pS240 S6, and Cyclin D1) in an expression study using breast cancer tissues. An immunohistochemical (IHC) prototype assay was established for each of the 4 antibodies (PTEN, pAkt, pS6, and Cyclin D1) using a polymer based detection system. The expression level of each biomarker was analyzed in 29 formalin-fixed paraffin-embedded ER positive breast cancer tissues using the prototype assays. A total of 27 of the 29 ER-positive breast cancer tissues were PR positive. All 29 tissues were positive for pS6 and Cyclin D1. 28/29 tissues were positive for pAkt and 25/29 tissues were PTEN positive. All 4 biomarkers showed a range of expression in the breast cancer tissues tested, with Cyclin D1 having a slightly higher (medium to high) expression range. PTEN negative and PTEN low expression tissues demonstrated mainly low to medium level of pAkt but medium to high level of pS6 and Cyclin D1 expression. The pAkt negative tissue showed low level PTEN and pS6 expression but high level Cyclin D1 expression.  Due to the small sample size in this study and the small number of PTEN null samples it was not possible to establish a correlation between the 4 biomarkers tested. However, all 4 PTEN null tissues demonstrated low to medium level pAkt and medium to high level pS6 and Cyclin D1 expression, indicating a possible link in their expression levels. A larger study using these prototype biomarker assays (PTEN, pS473 Akt, pS240 S6, and Cyclin D1) might be useful to further elucidate a possible interrelationship between these biomarkers in different tumor types.
TCT-696 Cardiac Output and Cerebral Blood Flow in Patients With Severe Aortic Valve Stenosis Undergoing Transcatheter Aortic Valve Implantation
Authors: Wieneke Vlastra, Anne-Sophie Bronzwaer, Adriaan Versteeg, Esther Bron, Charles Majoie, Mat Daemen, Jan Baan, Jan Piek, Ronak Delewi
Journal: Journal of the American College of Cardiology (2019)
Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia
Authors: Elizabeth Alexander, Lisa Goldberg, Anita F. Das, Gregory J. Moran, Christian Sandrock, Leanne B. Gasink, Patricia Spera, Carolyn Sweeney, Susanne Paukner, Wolfgang W. Wicha, Steven P. Gelone, Jennifer Schranz
Journal: JAMA (2019)

New antibacterials are needed to treat community-acquired bacterial pneumonia (CABP) because of growing antibacterial resistance and safety concerns with standard care.To evaluate the efficacy and adverse events of a 5-day oral lefamulin regimen in patients with CABP.A phase 3, noninferiority randomized clinical trial conducted at 99 sites in 19 countries that included adults aged 18 years or older with a Pneumonia Outcomes Research Team (PORT) risk class of II, III, or IV; radiographically documented pneumonia; acute illness; 3 or more CABP symptoms; and 2 or more vital sign abnormalities. The first patient visit was on August 30, 2016, and patients were followed up for 30 days; the final follow-up visit was on January 2, 2018.Patients were randomized 1:1 to receive oral lefamulin (600 mg every 12 hours for 5 days; n = 370) or moxifloxacin (400 mg every 24 hours for 7 days; n = 368).The US Food and Drug Administration (FDA) primary end point was early clinical response at 96 hours (within a 24-hour window) after the first dose of either study drug in the intent-to-treat (ITT) population (all randomized patients). Responders were defined as alive, showing improvement in 2 or more of the 4 CABP symptoms, having no worsening of any CABP symptoms, and not receiving any nonstudy antibacterial drug for current CABP episode. The European Medicines Agency coprimary end points (FDA secondary end points) were investigator assessment of clinical response at test of cure (5-10 days after last dose) in the modified ITT population and in the clinically evaluable population. The noninferiority margin was 10% for early clinical response and investigator assessment of clinical response.Among 738 randomized patients (mean age, 57.5 years; 351 women [47.6%]; 360 had a PORT risk class of III or IV [48.8%]), 707 (95.8%) completed the trial. Early clinical response rates were 90.8% with lefamulin and 90.8% with moxifloxacin (difference, 0.1% [1-sided 97.5% CI, -4.4% to ∞]). Rates of investigator assessment of clinical response success were 87.5% with lefamulin and 89.1% with moxifloxacin in the modified ITT population (difference, -1.6% [1-sided 97.5% CI, -6.3% to ∞]) and 89.7% and 93.6%, respectively, in the clinically evaluable population (difference, -3.9% [1-sided 97.5% CI, -8.2% to ∞]) at test of cure. The most frequently reported treatment-emergent adverse events were gastrointestinal (diarrhea: 45/368 [12.2%] in lefamulin group and 4/368 [1.1%] in moxifloxacin group; nausea: 19/368 [5.2%] in lefamulin group and 7/368 [1.9%] in moxifloxacin group).Among patients with CABP, 5-day oral lefamulin was noninferior to 7-day oral moxifloxacin with respect to early clinical response at 96 hours after first dose.ClinicalTrials.gov Identifier: NCT02813694; European Clinical Trials Identifier: 2015-004782-92.
Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet’s Pathway to Prevention
Authors: Emily K. Sims, Susan Geyer, Suzanne Bennett Johnson, Ingrid Libman, Laura M. Jacobsen, David Boulware, Lisa E. Rafkin, Della Matheson, Mark A. Atkinson, Henry Rodriguez, Maria Spall, Helena Elding Larsson, Diane K. Wherrett, Carla J. Greenbaum, Jeffrey Krischer, Linda A. DiMeglio
Journal: Diabetes Care (2019)

To better understand potential facilitators of individual engagement in type 1 diabetes natural history and prevention studies through analysis of enrollment data in the TrialNet Pathway to Prevention (PTP) study.We used multivariable logistic regression models to examine continued engagement of eligible participants at two time points: 1) the return visit after screening to confirm an initial autoantibody-positive (Ab+) test result and 2) the initial oral glucose tolerance test (OGTT) for enrollment into the monitoring protocol.Of 5,387 subjects who screened positive for a single autoantibody (Ab), 4,204 (78%) returned for confirmatory Ab testing. Younger age was associated with increased odds of returning for Ab confirmation (age <12 years vs. >18 years: odds ratio [OR] 2.12, P < 0.0001). Racial and ethnic minorities were less likely to return for confirmation, particularly nonwhite non-Hispanic (OR 0.50, P < 0.0001) and Hispanic (OR 0.69, P = 0.0001) relative to non-Hispanic white subjects. Of 8,234 subjects, 5,442 (66%) were identified as eligible to be enrolled in PTP OGTT monitoring. Here, younger age and identification as multiple Ab+ were associated with increased odds of returning for OGTT monitoring (age <12 years vs. >18 years: OR 1.43, P < 0.0001; multiple Ab+: OR 1.36, P < 0.0001). Parents were less likely to enroll into monitoring than other relatives (OR 0.78, P = 0.004). Site-specific factors, including site volume and U.S. site versus international site, were also associated with differences in rates of return for Ab+ confirmation and enrollment into monitoring.These data confirm clear differences between successfully enrolled populations and those lost to follow-up, which can serve to identify strategies to increase ongoing participation.
TCT-258 Outcomes of Residual Trivial and Mild Aortic Regurgitation After Transcatheter Aortic Valve Replacement
Authors: Johnny Chahine, Amer N. Kadri, Oscar Perez, Hassan Lak, Rama Dilip Gajulapalli, Mohamed Gad, James Yun, Lars Svensson, Serge Harb, Samir Kapadia
Journal: Journal of the American College of Cardiology (2019)
TCT-122 Trends and Outcomes of Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction in Patients With Opioid Abuse: Review From a National Database
Authors: Tiago Araujo, Sagar Ranka, Juan Del Cid Fratti, Omid Behnamfar, Moinuddin Syed, Abhushan Poudyal, Neha Yadav
Journal: Journal of the American College of Cardiology (2019)